Saturday, October 14, 2023
This conference has already taken place.
Description
Radiologists and technologists will jointly attend the sessions which will focus on important areas of shared responsibility and will promote a dialogue between registrants and faculty regarding problems encountered in the practice setting.
ASRT has approved this conference for 9.0 Category A Credits.
This is a Virtual conference only, using Zoom. You will be sent an email to the email address you state on your registration.
For pricing information, see pricing tab below.
Dates and Times
Start: 10/14/2023 7:00 AM
End: 10/14/2023 5:00 PM
Objectives
- Describe the pathology of ILC as it relates to imaging.
- List ways that ILC differs from IDC regarding imaging, surgical outcomes and metastatic pattern.
- Provide the differential diagnosis of architectural distortion and how the entities may be distinguished.
- Identify worrisome features of masses on mammography and ultrasound.
- Accurately assess interval change in breast masses.
- Reliably distinguish cystic and solid features of masses.
- Describe the radiology-pathology correlation of DCIS on mammography and ultrasound.
- Understand the differing appearances of low vs. high grade DCIS on mammography.
- Describe the non-calcified appearances of DCIS on mammography and US.
- Understand adaptive vs. maladaptive responses to bad news.
- Describe several ways to manage patients with maladaptive responses.
- Pros and cons of newly available breast cancer biopsy devices.
- Establish a coherent follow-up imaging protocol for breast biopsies.
- Properly choose a percutaneous biopsy clip.
- Differentiate suspicious non-mas enhancement (NME) from non-suspicious finding.
- Describe the use of kinetics in the management of NME.
- Describe mass findings on DCIS on MRI.
- Describe the equipment and technique of contrast-enhanced mammography (CEM).
- Distinguish suspicious CEM findings compared with background parenchymal enhancement.
- Discuss the finances and barriers to patient acceptance of CEM.
- Compare international breast cancer incidence rates and screening strategies.
- Compare international treatment regimes and survival rates.
- Recognize race-based disparities for screening and survival in the United States.
- Recount the ongoing genetic breakthroughs in oncogene screening.
- Explain the mechanism behind phenotypic manifestations of oncogene expression.
- Review the targeted gene therapies now available and under review.
- Identify and correct common breast MRI artifacts.
- Describe characteristics of masses on MRI that drive management.
- Describe management of findings on staging MRI and neoadjuvant therapy.
- Implement clinically relevant decision-making in difficult cases, as presented in an interactive, real-time audience participation session.
- Appropriately use the ACR Lexicon with difficult breast imaging cases.
Agenda
Pricing
| Tier | Price |
|---|---|
| Physicians | $235.00 |
| Retired Physicians | $210.00 |
| Residents, Radiologic Technologists and Other Healthcare Professionals | $210.00 |
| Registration after October 9th - add additional $50 - Physicians | $285.00 |
| Registration after October 9th - add additional $50 - Retired Physicians | $260.00 |
| Registration after October 9th - add additional $50 - Residents, Radiologic Technologists & Other Healthcare Professionals | $260.00 |
Speakers
Panels
Accreditation
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.